Stryker sells Bone Morphogenetic Protein assets (BMP-7) to a pharma company

Mariel Therapeutics to Acquire Stryker's BMP-7 Assets (HealthPointCapital)
The biopharmaceutical company, Mariel Therapeutics, entered into a definitive agreement to acquire Stryker's Bone Morphogenetic Protein-7 (BMP-7) assets, intended for the potential treatment of osteoarthritis (OA), chronic kidney disease (CKD) and other organ fibrosis conditions, lupus, and obesity.
BMP-7, which has been a long road to commercialization for Stryker, is a recombinant (artificial) version of a naturally occurring growth factor that encourages mesenchymal stem cells to differentiate into new bone.
Under th...